EVOLVE 101
Alternative Names: EV-101 - EvolveImmune Therapeutics; EVOLVE-101Latest Information Update: 28 Aug 2026
At a glance
- Originator EvolveImmune Therapeutics
- Class Antibodies; Antineoplastics; Immunotherapies; Recombinant proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Haematological malignancies
Most Recent Events
- 28 Aug 2026 No recent reports of development identified for research development in Acute-myeloid-leukaemia in USA (Parenteral)
- 28 Aug 2026 No recent reports of development identified for research development in Haematological-malignancies in USA (Parenteral)
- 24 Oct 2022 EvolveImmune Therapeutics plans a first-in-human clinical trial in Acute myeloid leukaemia and Haematological malignancies in 2024